HER2 in Focus: Biomarker Insights and Therapeutic Advancements Across Solid Tumors

Program Description

Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver that is prevalent across various solid tumors. Its overexpression or gene amplification leads to uncontrolled cell proliferation across solid tumor types, making it a key biomarker in precision oncology. This webinar provides a foundational understanding of HER2 pathobiology, its role in tumor cell growth, its prevalence, and its prognostic implications across key tumor types, including breast, gastrointestinal, gynecologic, genitourinary, and lung cancers. The core focus will be on evaluating the rapidly expanding landscape of current and emerging HER2-directed therapies. The mechanisms of action, FDA-approved indications, and recent clinical evidence for HER2-directed therapies, including monoclonal antibodies, tyrosine kinase inhibitors, antibody-drug conjugates, and bispecific antibodies, will be explored. This detailed pharmacological and clinical review will equip oncology pharmacists to effectively evaluate, select, and sequence HER2-targeted treatments in evolving clinical practice.

Target Audience: Health System Pharmacist, Oncology Pharmacist

Type of Activity: Application
Release date: December 19, 2025
Expiration date: December 19, 2026
Learner level: Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Explain the role of HER2 as a biomarker in the diagnosis and treatment of breast, gastrointestinal, gynecologic, genitourinary, and lung cancers, emphasizing its clinical relevance and prognostic implications.
2. Identify current and emerging HER2-directed therapies, including monoclonal antibodies, tyrosine kinase inhibitors (TKIs), antibody-drug conjugates (ADCs), and bispecific antibodies (BsAbs)
3. Analyze recent clinical evidence and advancements in HER2-targeted treatments